Veru Inc. VERU | NASDAQ
|2026-10-01
|F&G 45
|RSI 56.0
Company Overview:
10 Year VERU Performance Metrics:
VERU Dividend Charts
Unlock All Reports & Research Dividend Stocks like a BOSS!
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
VERU Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
VERU Dividends Info:
VERU Dividend History: Dates, Payments & Yield list
Below is a schedule of all VERU dividend payments, ex-dates, share price on the day of the payment as well as the annualized yield & forward yield
| Ex-Date | Payment Date | Amount | Yield | Forward Yield | Price on Ex-Date |
|---|---|---|---|---|---|
| 04/28/2014 | 05/07/2014 | $0.070 | 0.37% | 0.41% | $68.90 |
| 01/27/2014 | 02/05/2014 | $0.070 | 0.35% | 0.4% | $70.00 |
| 10/28/2013 | 11/06/2013 | $0.070 | 0.28% | 0.3% | $92.80 |
| 07/29/2013 | 08/07/2013 | $0.070 | 0.31% | 0.3% | $92.20 |
| 04/29/2013 | 05/08/2013 | $0.070 | 0.36% | 0.35% | $80.70 |
| 01/28/2013 | 02/06/2013 | $0.060 | 0.31% | 0.32% | $74.50 |
| 10/29/2012 | 11/07/2012 | $0.060 | 0.33% | 0.35% | $68.80 |
| 07/30/2012 | 08/08/2012 | $0.060 | 0.42% | 0.4% | $59.70 |
| 04/30/2012 | 05/09/2012 | $0.060 | 0.4% | 0.43% | $55.60 |
| 01/30/2012 | 02/09/2012 | $0.050 | 0.38% | 0.37% | $53.50 |
| 10/31/2011 | 11/09/2011 | $0.050 | 0.44% | 0.47% | $43.00 |
| 07/29/2011 | 08/09/2011 | $0.050 | 0.43% | 0.44% | $45.70 |
| 04/29/2011 | 05/10/2011 | $0.050 | 0.42% | 0.39% | $50.70 |
| 01/27/2011 | 02/07/2011 | $0.050 | 0.37% | 0.39% | $51.90 |
| 11/01/2010 | 11/10/2010 | $0.050 | 0.36% | 0.32% | $63.00 |
| 08/02/2010 | 08/11/2010 | $0.050 | 0.4% | 0.45% | $44.20 |
| 04/21/2010 | 05/12/2010 | $0.050 | 0.3% | 0.3% | $66.40 |
| 01/27/2010 | 02/16/2010 | $0.050 | 0.37% | 0.36% | $56.30 |
Projected Future Returns & Dividends for VERU
Based on past 10-year performance, here are VERU growth metrics:
Share price CAGR of -14.52%
Dividend CAGR of +8.3%
Using VERU CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| VERU (DRIP) | VERU - No DRIP | |
|---|---|---|
| Current Price | $2.54 | $2.54 |
| Start Shares | 3,937.01 | 3,937.01 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 73,708.17 | 3,937.01 |
| Dividends Payment | $0.07 | $0.07 |
| Annual Dividends | $21,777 | $1,163 |
| Yield on cost | 217.77% | 11.63% |
| Share Price | $0.53 | $0.53 |
| Total Dividends | $58,445 | $13,669 |
| Final Value | $38,978 | $15,751 |
NOTE: Above numbers are our estimate based on VERU's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
Company Info
Veru Inc. (VERU) had its IPO on 1999-02-11, and is traded on NASDAQ stock exchange.
Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.
VERU website: https://www.verupharma.com
Get Full Access to All Reports with DRIPCalc PRO
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
- Unlimited Portfolio Tracker
- Portfolio - Lots/Sales/Dividends
- Portfolio Auto-DRIP
- Buy/Sell Signals Dashboard
- Stock Fundamentals
- Compare Stocks Side-by-Side
- Revenue & EPS Estimates
- DCF Valuation Modeling
- Everything in Pro
- YieldMax PNL Tracker
- YieldMax NAV Erosion Alerts
- YM ETFs Trend Signals
- 9/21 EMA Trend Signals
- Stocks Dashboard
- Everything in Premium
- 15min & 1hr Intraday Signals
- Group & weekly ETF estimates
- YouTuber Mode
- Trades summary + CSV export
- Priority data & support
DCF Model — VERU
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
| Year | FCF | Implied price |
|---|
